Correlation Engine 2.0
Clear Search sequence regions


  • adenocarcinoma lung (1)
  • cataract (1)
  • chemosis (5)
  • conjunctiva (1)
  • crizotinib (9)
  • edema (5)
  • eyedrops (1)
  • humans (1)
  • layer (1)
  • lung (1)
  • optic nerve (1)
  • patient (1)
  • photopsia (1)
  • physicians (1)
  • segment (2)
  • steroid (1)
  • Sizes of these terms reflect their relevance to your search.

    Crizotinib, a targeted molecular therapy drug which inhibits tyrosine kinase, is approved for treatment of non-small cell lung carcinoma which has some ocular side effects like photopsia and delayed dark adaptation.This report documents a unique case of persistent conjunctival chemosis likely due to side effects of crizotinib therapy. A 64-year-old gentleman on crizotinib for metastatic adenocarcinoma of the lung presented with conjunctival chemosis in right eye which appeared 1 month after uneventful clear corneal phacoemulsification surgery. The patient was on crizotinib 250 mg twice a day started 2 months before cataract surgery. Clinical examination revealed marked inferior bulbar conjunctival edema of the right eye. Anterior segment optical coherence tomography, slit-lamp photographs, and magnetic resonance imaging orbit and systemic investigation were done to rule out other causes of conjunctival edema. Magnetic resonance imaging shows conjunctival and preseptal edema around both eye and thinning of the optic nerve in the right eye. Anterior segment optical coherence tomography revealed elevated hyper-reflective thickened conjunctival layer with dilated empty thin wall dark spaces of varying caliber. Chemosis was persisted for the next 3 months and not responded to oral acetazolamide, topical steroid and decongestive eyedrops. After 3 months, crizotinib was discontinued by oncologist due to drug intolerance and surprisingly within 1 week, the conjunctival edema was disappeared totally. To the best of the authors' knowledge, this is the first reported case of persistent unilateral non-inflammatory conjunctival chemosis caused by crizotinib. The physicians should be vigilant about these complications. Copyright © 2020 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.

    Citation

    Joyeeta Das, Nibedita Das. Chronic Conjunctival Chemosis-A New Ocular Side Effect of Crizotinib. Ophthalmic plastic and reconstructive surgery. 2021 Jan-Feb 01;37(1):e18-e21

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32501881

    View Full Text